Lifeloc Technologies Narrows Q1 Loss to $(0.06) EPS Amid Flat Revenue, New Product in Beta
summarizeSummary
Lifeloc Technologies reported first-quarter 2026 results, showing a narrowed net loss of $(152.7K), or $(0.06) diluted EPS, an improvement from $(0.11) EPS in the prior-year quarter, on essentially flat revenue of $2.29 million. This improvement in profitability is a positive development, especially considering the company's substantially increased net loss for 2025 and the recent $500,000 loan secured from its CFO and Chairman to fund operations. The company also announced that its SpinDetect™ oral-fluid analyzer entered beta testing with a targeted commercial launch in 2026, signaling potential future growth. For a micro-cap company, demonstrating an improving financial trend and advancing product development are crucial for operational stability and investor sentiment. Traders will monitor the commercial launch of SpinDetect™ and the company's path to sustained profitability.
At the time of this announcement, LCTC was trading at $1.90 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $1.75 to $5.58. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.